Acibadem City Clinic Diagnostic And Consultation Center Ltd.
- Address
- Bulevard Tsarigradsko Shose 66a, 1784 Sofia, Bulgaria
Acibadem City Clinic Diagnostic And Consultation Center Ltd.
Acibadem City Clinic Diagnostic And Consultation Center Ltd. is a leading clinical research facility specializing in autoimmune and inflammatory disorders. The center demonstrates particular expertise in conducting Phase 2 and Phase 3 clinical trials evaluating novel biologic therapies and disease-modifying treatments across multiple therapeutic areas. Their research portfolio reflects a strong commitment to advancing treatment options for patients with complex chronic conditions requiring specialized care.
- Psoriatic Arthritis: investigating biologic DMARDs including deucravacitinib and sonelokimab in both biologic-naïve patients and those with anti-TNFα inadequate response
- Inflammatory Bowel Disease: conducting trials in moderate to severe Crohn's Disease and Ulcerative Colitis, evaluating targeted therapies and novel biologics
- Systemic Lupus Erythematosus: evaluating oral and systemic therapies for moderate to severe SLE, including long-term safety and efficacy assessments
- Metabolic Liver Disease: researching combination therapies for Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with liver fibrosis
The center's research infrastructure supports comprehensive evaluation of both efficacy and safety endpoints in complex autoimmune conditions, including long-term extension studies. Their clinical trial portfolio demonstrates capability in managing placebo-controlled, double-blind, randomized studies with active reference comparators, positioning them as a key contributor to the development of next-generation immunomodulatory therapies for rheumatologic, gastroenterologic, and metabolic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Acibadem City Clinic Diagnostic And Consultation Center Ltd.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allopurinol | 1 | Unknown | 2024-04-09 | 2024-04-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.